The Beauty Health Company (NASDAQ:SKIN) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of The Beauty Health Company (NASDAQ:SKIN) have earned a consensus rating of “Reduce” from the twelve research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.29.

A number of equities analysts recently issued reports on the company. TD Cowen decreased their price objective on Beauty Health from $4.00 to $3.00 and set a “hold” rating for the company in a report on Monday, May 13th. Piper Sandler cut their target price on Beauty Health from $3.00 to $2.50 and set an “underweight” rating for the company in a research report on Friday, May 10th. Canaccord Genuity Group upped their target price on Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research report on Thursday, March 14th. DA Davidson restated a “buy” rating and issued a $5.00 target price on shares of Beauty Health in a research report on Monday, May 13th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $4.00 target price (up from $3.00) on shares of Beauty Health in a research report on Wednesday, March 13th.

Beauty Health Stock Performance

Shares of SKIN stock opened at $2.64 on Thursday. Beauty Health has a 12-month low of $1.35 and a 12-month high of $10.60. The firm has a market capitalization of $325.86 million, a price-to-earnings ratio of -3.77 and a beta of 1.13. The business has a 50 day simple moving average of $3.52 and a 200 day simple moving average of $3.18. The company has a debt-to-equity ratio of 10.51, a current ratio of 6.57 and a quick ratio of 5.55.

Beauty Health (NASDAQ:SKIN) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. Beauty Health had a negative return on equity of 0.02% and a negative net margin of 20.48%. The business had revenue of $81.40 million during the quarter, compared to analyst estimates of $80.56 million. During the same period in the prior year, the company posted ($0.17) EPS. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, equities research analysts anticipate that Beauty Health will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Beauty Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Senvest Management LLC lifted its position in shares of Beauty Health by 30.8% during the 3rd quarter. Senvest Management LLC now owns 8,937,381 shares of the company’s stock valued at $53,803,000 after acquiring an additional 2,106,622 shares during the last quarter. Braidwell LP purchased a new stake in shares of Beauty Health in the third quarter valued at $9,790,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Beauty Health in the first quarter valued at $4,297,000. Glendon Capital Management LP lifted its holdings in shares of Beauty Health by 46.0% in the third quarter. Glendon Capital Management LP now owns 636,954 shares of the company’s stock valued at $3,834,000 after purchasing an additional 200,800 shares in the last quarter. Finally, Pasadena Private Wealth LLC purchased a new stake in shares of Beauty Health in the fourth quarter valued at $1,857,000. Institutional investors and hedge funds own 93.26% of the company’s stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.